Burning Rock Biotech (BNR)
(Delayed Data from NSDQ)
$7.20 USD
+0.94 (15.02%)
Updated Jul 15, 2024 03:59 PM ET
After-Market: $7.25 +0.05 (0.69%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BNR 7.20 +0.94(15.02%)
Will BNR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BNR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BNR
Is Burning Rock Biotech (BNR) Outperforming Other Business Services Stocks This Year?
Mogo Inc (MOGO) Reports Q4 Loss, Tops Revenue Estimates
BNR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Usio Inc (USIO) Reports Q4 Loss, Tops Revenue Estimates
Outbrain Inc. (OB) Reports Q4 Loss, Tops Revenue Estimates
Burning Rock Biotech Limited Sponsored ADR (BNR) Upgraded to Buy: What Does It Mean for the Stock?
Other News for BNR
GLOBAL BROKER RATINGS: UBS cuts GSK, Jefferies raises FinecoBank
IN BRIEF: Brenntag acquires Industrial Chemicals Corporation
Baader Bank Remains a Buy on Brenntag AG (0MPT)
GLOBAL BROKER RATINGS: Jefferies cuts Hargreaves Lansdown to 'hold'
GLOBAL BROKER RATINGS: JPMorgan raises Adobe; Stifel raises Lanxess